Chimerix’s (CMRX) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Chimerix (NASDAQ:CMRX) in a report released on Tuesday,Benzinga reports. They currently have a $11.00 target price on the biopharmaceutical company’s stock.

Separately, Wedbush restated an “outperform” rating and issued a $6.00 target price on shares of Chimerix in a research note on Tuesday, December 10th.

Chimerix Stock Up 1.8 %

Shares of CMRX stock opened at $5.17 on Tuesday. The business has a 50 day moving average of $3.72 and a two-hundred day moving average of $1.92. Chimerix has a 52 week low of $0.75 and a 52 week high of $5.53. The company has a market cap of $464.99 million, a P/E ratio of -5.50 and a beta of 0.35.

Insider Buying and Selling at Chimerix

In other news, CEO Michael T. Andriole sold 7,370 shares of the business’s stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $4.52, for a total transaction of $33,312.40. Following the completion of the transaction, the chief executive officer now directly owns 609,603 shares in the company, valued at approximately $2,755,405.56. The trade was a 1.19 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders sold a total of 20,760 shares of company stock worth $91,175 over the last ninety days. Company insiders own 13.10% of the company’s stock.

Hedge Funds Weigh In On Chimerix

Hedge funds and other institutional investors have recently made changes to their positions in the business. Bender Robert & Associates acquired a new position in shares of Chimerix during the fourth quarter worth approximately $37,000. Susquehanna Fundamental Investments LLC acquired a new position in shares of Chimerix during the fourth quarter worth approximately $59,000. Jane Street Group LLC acquired a new position in shares of Chimerix during the fourth quarter worth approximately $62,000. Diadema Partners LP acquired a new position in shares of Chimerix during the fourth quarter worth approximately $101,000. Finally, Squarepoint Ops LLC acquired a new position in shares of Chimerix during the fourth quarter worth approximately $130,000. 45.42% of the stock is currently owned by institutional investors and hedge funds.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.